PLP1 and myeloid sarcoma: When the ELISA data from MS patients and controls shown in Figure 2A was assessed on the basis of carriage of these PLP response-permissive HLA types, there was still a highly significant difference between MS patients and controls for the PLP response-permissive HLA types, but not for those individuals who do not carry these HLA types (Figure 4).